PCN83 BUDGET IMPACT ANALYSIS OF OSIMERTINIB VERSUS PEMETREXED FOR THE SECOND-LINE TREATMENT OF ADVANCED LUNG CANCER WITH T790M POSITIVE FROM PUBLIC HEALTH PERSPECTIVE IN CHILE

Abstract

Assess the budget impact of Osimertinib (Osim) versus Pemetrexed (PEM) for the second-line treatment of advanced lung cancer with T790m (aLC-T790m) mutated from the perspective of the Chilean public healthcare system A cohort of patient with aLC-T790m using a constructed data with prevalence and incidence for lung cancer distributed by sex and proportions for non-small cell lung cancer, EGFR mutated, eligible patient for systemic treatment, which was provided for international literature, clinical experts and real-world data from Chile, in accordance with ISPOR principle good practice. Expected costs were measured in Chilean pesos (1 USD = 680 CLP$). The analysis was made from the perspective of Chilean public health assuming a 100% reimbursement. We considered pharmacological, drug administration, follow-up cost and adverse event. Annual costs were estimated considering a time horizon of five years. The budget impact was presented for the price sent by the company. When considering current full monthly price of US$8,647.87 monthly an additional of US$1,779,692 relative to PEM are needed in the first year, and US$5,526,411 for the second year. Moreover, Osim presented monetary savings in all the years studied for the items, drug administration and adverse event. Despite for the highest cost for Osim, items like cost for drug administration and adverse event, were significantly favorable for innovator drug. To summary, Osim is more expensive than PEM and shows an increasing cost with the time. Nevertheless, the patients treated with Osim lives more time than PEM generating highest cost in the time